Literature DB >> 31907215

Primary Pancreatic lymphoma: a rare clinical entity.

Louise Dunphy1, Syed Hussain Abbas2, Ihsan Al Shoek2, Wassim Al-Salti3.   

Abstract

Primary pancreatic lymphoma is a rare clinical entity representing <0.5% of pancreatic cancers and 1% of extranodal lymphomas. Due to the paucity of cases described in the literature, its clinicopathological features, differential diagnosis, optimal therapy and outcomes are not well defined. As the clinical manifestations are often non-specific, it can create a diagnostic pitfall for the unwary physician. Preoperative distinction of adenocarcinoma and primary pancreatic lymphoma is critical since the management and prognosis of these malignancies are mutually exclusive. Due to its rarity, epidemiological studies have been difficult to conduct. Chemotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin and vincristine) has proven to be effective. The authors present the case of a 52-year-old man with epigastric pain and obstructive jaundice. Further investigation with a CT of the abdomen and pelvis showed a low attenuation mass in the head of the pancreas measuring 35×25 mm, suspicious for malignancy. The mass involved the common bile duct distally causing moderate retrograde intrahepatic and extrahepatic biliary tree dilation of 14 mm. He underwent endoscopic retrograde cholangiopancreatography, sphincterotomy and insertion of a stent. Core biopsies confirmed the diagnosis of a high-grade B cell pancreas lymphoma. He started treatment with R-CHOP and prednisolone. Due to disease progression, he started treatment with DA-EPOCH-R (etoposide phosphate, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride and rituximab). There was no clinical response, and treatment with RICE (rituximab, ifosfamide, carboplatin and etoposide) was initiated. He showed partial response and was under consideration for chimeric antigen receptor T cell therapy. He deteriorated clinically and succumbed to his disease 5 months following his initial presentation. This paper will provide an overview of the spectrum of haematological malignancies and describe useful features in distinguishing primary lymphoma of the pancreas from an adenocarcinoma, hence avoiding its surgical resection. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Emergency medicine; General surgery

Mesh:

Year:  2020        PMID: 31907215      PMCID: PMC6954783          DOI: 10.1136/bcr-2019-231292

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

1.  Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis.

Authors:  I M DAWSON; J S CORNES; B C MORSON
Journal:  Br J Surg       Date:  1961-07       Impact factor: 6.939

2.  Primary pancreatic lymphoma or secondary involvement: what is the difference?

Authors:  Taylan Kav; Aynur G Soyuoz; Kadri Altundag; Yusuf Bayraktar
Journal:  JOP       Date:  2010-09-06

3.  Imaging findings in pancreatic lymphoma: differential aspects.

Authors:  E M Merkle; G N Bender; H J Brambs
Journal:  AJR Am J Roentgenol       Date:  2000-03       Impact factor: 3.959

4.  Pancreaticoduodenectomy for primary pancreatic lymphoma.

Authors:  Jessica F Rose; T Jie; Philip Usera; E S Ong
Journal:  Gastrointest Cancer Res       Date:  2012-01

Review 5.  Primary pancreatic lymphomas.

Authors:  Muhammad Wasif Saif
Journal:  JOP       Date:  2006-05-09

Review 6.  Primary pancreatic lymphoma: diagnostic and therapeutic dilemma.

Authors:  Narendra Battula; Parthi Srinivasan; Andreas Prachalias; Mohamed Rela; Nigel Heaton
Journal:  Pancreas       Date:  2006-08       Impact factor: 3.327

7.  Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma.

Authors:  Chung-Che Chang; Sara McClintock; Ronald P Cleveland; Trent Trzpuc; David H Vesole; Brent Logan; Andre Kajdacsy-Balla; Sherrie L Perkins
Journal:  Am J Surg Pathol       Date:  2004-04       Impact factor: 6.394

8.  Primary pancreatic lymphoma: Report of three cases with review of literature.

Authors:  Altaf Gauhar Haji; Shekhar Sharma; K Abdul Majeed; D K Vijaykumar; K Pavithran; M Dinesh
Journal:  Indian J Med Paediatr Oncol       Date:  2009-01

9.  Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience.

Authors:  C Tondini; R Giardini; F Bozzetti; P Valagussa; A Santoro; R Bertulli; M Balzarotti; A Rocca; F Lombardi; A J Ferreri
Journal:  Ann Oncol       Date:  1993-12       Impact factor: 32.976

10.  Primary pancreatic lymphoma: two case reports and a literature review.

Authors:  Lili Yu; Yajun Chen; Ligang Xing
Journal:  Onco Targets Ther       Date:  2017-03-20       Impact factor: 4.147

View more
  2 in total

Review 1.  Primary Pancreatic Lymphoma: Recommendations for Diagnosis and Management.

Authors:  Davide Facchinelli; Enrico Boninsegna; Carlo Visco; Cristina Tecchio
Journal:  J Blood Med       Date:  2021-05-05

Review 2.  Primary hepatopancreatobiliary lymphoma: Pathogenesis, diagnosis, and management.

Authors:  Qianwen Wang; Kangze Wu; Xuzhao Zhang; Yang Liu; Zhouyi Sun; Shumei Wei; Bo Zhang
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.